Debt
posted on
Apr 02, 2022 01:01PM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
For those wondering how the lights stay on, as of Jan. 31/22 there was a $1.5 million loan from Newsoara and almost $1.9 million of Promissory Notes out. The Newsoara loan was taken March/21 and subsequent to Jan.31/22 the maturity date was amended to June 30/22. Details on the Promissory Notes are copied below. $1 million of it is at 11%.
Promissory notes (continued)
As at January 31, 2022, promissory notes totaling $1.9 million are due to three related party lenders. During the nine months ended January 31, 2022:
• the Chief Executive Officer / Chairman of the Company lent an additional CAD$0.5 million and was repaid CAD$0.4 million (the outstanding $0.6 million (CAD$0.8 million) promissory note bears interest at 5%, is payable on demand and is secured);
• another director of the Company lent an additional CAD$0.1 million to the Company and was repaid CAD $0.1 million (the outstanding $0.2 million (CAD$0.3 million) promissory note bears interest at 5% per annum, is unsecured and is payable on demand);
• a relative of the Chief Executive Officer / Chairman of the Company lent an additional $0.7 million and was repaid $0.3 million (the outstanding $1.0 million promissory note bears interest at 11% per annum, is payable on demand and is secured);
• the Chief Financial Officer lent CAD$20 thousand and was repaid CAD$20 thousand (the promissory note bore interest at 8% per annum while it was outstanding); and
• a third party lent $63 thousand and was repaid $63 thousand (the promissory note bore interest at 8% per annum while it was outstanding).
In connection with the $0.7 million total promissory note advanced by a relative of the Chief Executive Officer / Chairman of the Company ($0.3 million was advanced in October 2021 and $0.4 million was advanced in January 2022), the Company issued a total of 350,000 warrants. Each warrant is exercisable at a price of $0.75 per underlying common share for a period of five years from the respective grant dates. The combined fair value of the 350,000 warrant